Drug intelligence / Profile preview

KLS-13022

Development stage: Preclinical
Lead developer: Neuropathix
Modality: Small Molecules
Administration: Topical

Overview

KLS-13022 is a preclinical-stage small molecule candidate being developed by Neuropathix for the treatment of over-the-counter (OTC) skin disorders, including pain, itch, and burn. Formulated as a topical cream, the compound is currently in the early discovery and optimization phase. Neuropathix aims to have the product ready for the OTC market by late 2026. The specific biological target has not been publicly disclosed, but the program leverages the company's focus on neuropathic and inflammatory conditions.

Beyond the preview

Go deeper on KLS-13022.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KLS-13022.

Explore the full profile